Browsing Centre for Clinical Pharmacology by Author "Hader, S"
Now showing items 1-4 of 4
-
Complete clinical cure of primary aldosteronism (PA) is predictable and sustained for at least two years
Goodchild, E; Wu, X; Senanayake, R; Bashari, W; Salsbury, J; Cabrera, C; Argentesi, G; O'Toole, S; MacFarlane, J; Laycock, K -
FRI156 Novel Radiolabeled Ligand, Para-chloro-2-[18F]fluoroethyletomidate (CETO) Is Equivalent To [11C]metomidate-PET (MTO) For The Lateralisation Of Primary Aldosteronism (PA)
Goodchild, E; Senanayake, R; Wu, X; Bashari, W; Salsbury, J; Argentesi, G; O'Toole, SM; McFarlane, J; Laycock, K; Gillett, D (The Endocrine Society, 2023-10-05) -
Novel radiolabeled ligand, Para-chloro-2-[ 18 F]fluoroethyletomidate (CETO) compared to [ 11 C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)
Goodchild, E; Senanayake, R; Wu, X; Bashari, W; Salsbury, J; Argentesi, G; O'Toole, S; MacFarlane, J; Laycock, K; Gillett, D -
[<SUP>11</SUP>C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial
Wu, X; Senanayake, R; Goodchild, E; Bashari, WA; Salsbury, J; Cabrera, CP; Argentesi, G; O'Toole, SM; Matson, M; Koo, B (2023)